# 3D Medicines Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/3d-medicines

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.3dmedcare.com
- Total disclosed funding: $124M
- Latest round: Series E (Mar 22, 2018)
- Investors on record: 8

## About

Established in 2010 and based in Shanghai, China, 3D Medicines Corporation is a biotechnology company which focuses on precision cancer care. The company has obtained some qualifications, such as National Specialized and Special New Little Giant, High-Tech Enterprise and Shanghai Small Giant Enterprise of Science and Technology. There are more than 1000 employees in the company. 3D Medicines Corporation has obtained approximately 200 patents and has set up research and development centers in US, and Singapore.

The company has built a comprehensive research and development platform, integrating equipment engineering, electrical, life science technology, materials science and artificial intelligence data analysis. 3D Medicines Corporation provides comprehensive integrated products and services for tumor diagnosis and treatment, covering peer diagnostic testing of tumor tissue and blood source samples. The company's main product is subcutaneous injection of anti-PD-L1 tumor immunotherapy antibodies.

## Funding rounds

- Series E, Mar 22, 2018 — DAAN Gene, Hanfor Capital, Xiamen Huarui Investment Management
- Series E, Nov 23, 2017, $101M — ChinaEquity Group, China Reform Holdings
- Series D, Nov 7, 2016 — Jinbang Capital
- Series D, Nov 16, 2015, $23M — Fang Fund Partners, Tasly Pharmaceutical Co., Ltd.
- Series C, Oct 8, 2014 — Fang Fund Partners

## Investors

- Fang Fund Partners (https://capitalatlas.ai/funds/fang-fund-partners) — Series C, Series D
- Tasly Pharmaceutical Co., Ltd. — Series D
- Jinbang Capital — Series D
- ChinaEquity Group (https://capitalatlas.ai/funds/chinaequity-group) — Series E
- China Reform Holdings (https://capitalatlas.ai/funds/china-reform-holdings) — Series E
- DAAN Gene — Series E
- Hanfor Capital (https://capitalatlas.ai/funds/hanfor-capital) — Series E
- Xiamen Huarui Investment Management — Series E